VERSANT HCV Genotype 2.0 Assay (LiPA)
FDA premarket approval P160016/S003 · decided 2019-04-05
Approval details
- PMA number
- P160016
- Supplement
- S003
- Supplement type
- 30-Day Notice
- Supplement reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Trade name
- VERSANT HCV Genotype 2.0 Assay (LiPA)
- Generic name
- Assay, genotyping, hepatitis c virus
- Applicant
- Fujirebio Europe N.V.
- Date received
- 2019-03-08
- Decision date
- 2019-04-05
- Days to decision
- 28 days
- Decision code
- OK30
- Product code
- OBF
- Advisory committee
- Microbiology
- Expedited review
- No
- Location
- Gent
- Statement
- Relocation of reagent manufacture from one building to another within the same establishment.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.